1
|
Johnson K, VandenHull A, Remund T, Pohlson K, Bares V, Wacker J, Kelly P. Short-term Cost Comparison of Systemic Heparin Therapy vs. Catheter Directed Thrombolysis for the Treatment of Massive and Submassive Pulmonary Embolism with Long-Term Chronic Pulmonary Hypertension Cost Model. S D Med 2021; 74:70-74. [PMID: 34161687 PMCID: PMC8232014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
INTRODUCTION Pulmonary embolism (PE) is a significant disease process that affects an estimated 117 cases per 100,000 person-years. Chronic pulmonary hypertension (CPH) is a long-term complication associated with acute PE which has a significant cost to treat, ranging from $98,000-117,000. METHODS A retrospective chart review of 341 patients from January 2011 to November 2018 who presented with massive or submassive PE and were treated with either systemic heparin therapy or catheter directed thrombolysis (CDT). The results of the short-term cost analysis and pulmonary hypertension rates from data collected was then used in a long-term cost model using a standardized 100 patient model. RESULTS Treatment with CDT resulted in fewer bleeding complications (4.2 percent vs. 13.8 percent, p=0.005), a shorter length of stay, a greater percentage of patients returning to their prior living conditions (89.0 percent vs. 79.3 percent, p=0.042), and a lower rate of chronic pulmonary hypertension at 12 months (6.3 percent vs. 15.9 percent, p=0.030) than those treated with systemic heparin. The expense of treatment utilizing CDT was greater than those undergoing systemic heparin treatment with a difference of approximately $31,000 (p=0.001) though our cost model showed the heparin group to have a higher cost over time. CONCLUSIONS For patients with massive or submassive PE, this study demonstrated a significant long-term cost savings and improved outcomes for patients treated with catheter directed thrombolysis when compared to systemic heparin administration.
Collapse
Affiliation(s)
- Kristopher Johnson
- General Surgery Residency Program, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota
| | | | | | | | | | | | - Patrick Kelly
- Sanford Health Vascular Surgery, Sioux Falls, South Dakota
- Department of Surgery, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota
| |
Collapse
|
2
|
Jorgensen BD, Malek M, VandenHull A, Remund T, Truong KC, Pohlson K, Kelly PW. A novel physician-assembled endograft for the repair of pararenal, paravisceral, Crawford type IV thoracoabdominal aortic aneurysms, and aneurysms requiring treatment after prior repair. J Vasc Surg 2020; 72:1897-1905.e2. [PMID: 32335306 DOI: 10.1016/j.jvs.2020.03.045] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Accepted: 03/18/2020] [Indexed: 10/24/2022]
Abstract
OBJECTIVE In the present study, we reviewed the 30-day and 1-year clinical results of the use of the investigational unitary manifold (UM) stent graft system (Sanford Health, Sioux Falls SDak) for the repair of Crawford type IV, pararenal, paravisceral, juxtarenal, and short-neck infrarenal aneurysms (<10 mm). METHODS The present study was a single-center, multiarm, prospective review of the first 44 patients who had undergone repair of Crawford type IV, pararenal, juxtarenal, and short-neck infrarenal aneurysms (<10 mm) using the physician-modified UM under a physician-sponsored investigational device exemption. The primary end point was freedom from major adverse events at 30 days, including all-cause mortality, myocardial infarction, stroke, paraplegia, bowel ischemia, respiratory failure, and renal failure. RESULTS Technical success was achieved in all 44 patients (100%), with a large number of these patients having undergone previous aortic repair (20 of 44; 45.5%). All the intended 170 visceral vessels (100%) had been successfully cannulated and stent grafted. No episodes of paraplegia or in-hospital deaths were recorded. One patient had died of aneurysm-related ischemic stroke (2.3%). The rate of transient nonclinically significant spinal cord ischemia was 4.5%. At the last follow-up, one reintervention had been required owing to branch patency from a thrombotic event. Of the 170 bridging stent grafts, 169 have remained patent through a mean follow-up of 8.8 months (range, 0-36 months). No type I or III endoleaks, migration, or component separation in the investigational device has occurred. CONCLUSIONS The early and midterm results with the use of the UM suggest it could be a viable option for the repair of Crawford type IV, pararenal, paravisceral, juxtarenal, and short-neck infrarenal aneurysms (<10 mm) without exposing patients to the increased risk of permanent spinal cord ischemia, renal failure, visceral vessel ischemia, or aneurysm-related mortality that results from open thoracoabdominal aortic aneurysm repair. The high technical success rate, in native and previous repairs, supports the utility of this device as a bail-out technique for failed endovascular aneurysm repair or proximal extension of disease after previous aortic repair. However, experience is limited, and this approach requires further study before widespread adoption.
Collapse
Affiliation(s)
| | - Mathew Malek
- University of South Dakota Sanford School of Medicine, Sioux Falls, SDak
| | | | | | | | | | - Patrick W Kelly
- Department of Vascular Surgery, Sanford Vascular Associates, Sanford Health, Sioux Falls, SDak.
| |
Collapse
|
3
|
Anderson JA, Lamichhane S, Fuglsby K, Remund T, Pohlson K, Evans R, Engebretson D, Kelly P. Development of drug-coated balloon for the treatment of multiple peripheral artery segments. J Vasc Surg 2019; 71:1750-1757.e7. [PMID: 31519510 DOI: 10.1016/j.jvs.2019.04.494] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2019] [Accepted: 04/21/2019] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Peripheral artery disease is the second most common cardiovascular disease. It can often occur in complex form when there is a presence of long, diffuse, and multiple lesions. Current treatments use either single long drug-coated balloons (DCBs) or multiple DCBs; however, treatment success is limited. The purpose of this study was to investigate the preclinical feasibility of our multiple-release Tailored Medical Devices DCB (MR-TMD-DCB) to treat multiple arterial segments using a single DCB. METHODS The MR-TMD-DCBs were developed using a two-layer coating approach. The DCBs were developed in a certified Current Good Manufacturing Practices facility using presterilized materials and reagent and then characterized for coating morphology, thermal and chemical changes, and in vitro particulate shedding. The drug loss, tissue uptake, and undelivered drug amounts were analyzed using an in vitro peripheral artery flow model and explanted pig arteries. Then, an in vivo survival study was performed using a healthy porcine model to measure the short-term drug uptake (seven swine; 14 treatments at day 1) and retention (seven swine; 14 treatments at day 7) in two different arterial segments after treatment with a single MR-TMD-DCB. RESULTS The coating on the MR-TMD-DCB was smooth and homogeneous with paclitaxel molecularly dispersed in its amorphous state. A negligible number of particulates were shed from the MR-TMD-DCB coating. A similar amount of drug was accurately delivered into two separate explanted arteries using a single MR-TMD-DCB during the in vitro flow model testing (707 ± 109 ng/mg in the first explanted artery and 783 ± 306 ng/mg in the second explanted artery). The MR-TMD-DCB treatment resulted in equivalent drug amounts in the two arterial segments at day 1 (63 ± 19 ng/mg in the first treatment site and 59 ±19 ng/mg in the second treatment site) and at day 7 (9 ± 6 ng/mg in the first treatment site and 10 ± 6 ng/mg in the second treatment site). In addition, the drug levels at each time point were in the clinically relevant range to prevent neointimal hyperplasia. CONCLUSIONS The MR-TMD-DCBs provided equivalent and clinically relevant drug retention levels into two different arterial segments. Thus, MR-TMD-DCBs can be used to accurately deliver drug into multiple arterial segments with the use of a single DCB. The clinical outcomes of these findings need further investigation. Future long-term pharmacokinetics and safety studies will be performed to evaluate the safety and efficacy of the MR-TMD-DCB.
Collapse
Affiliation(s)
| | | | - Kirby Fuglsby
- Department of Biomedical Engineering, University of South Dakota, Sioux Falls, SD
| | | | | | | | - Daniel Engebretson
- Tailored Medical Devices, Inc, Sioux Falls, SD; Department of Biomedical Engineering, University of South Dakota, Sioux Falls, SD
| | - Patrick Kelly
- Division of Vascular Surgery, Sanford Health, Sioux Falls, SD
| |
Collapse
|
4
|
Li N, Sanyour H, Remund T, Kelly P, Hong Z. Vascular extracellular matrix and fibroblasts-coculture directed differentiation of human mesenchymal stem cells toward smooth muscle-like cells for vascular tissue engineering. Materials Science and Engineering: C 2018; 93:61-69. [PMID: 30274093 DOI: 10.1016/j.msec.2018.07.061] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Accepted: 07/23/2018] [Indexed: 02/06/2023]
Abstract
Construction of an artificial vascular graft is widely considered a promising strategy in vascular tissue engineering. However, limited sources of functional vascular smooth muscle cells (VSMCs) remain a major obstacle in vascular tissue engineering. In this study, we innovatively developed an approach to obtain functional VSMCs by onsite differentiating human bone marrow-derived mesenchymal stem cells (MSCs) directed by decellularized extracellular matrix (ECM) and fibroblasts. The resulting cells and ECM-cells constructs were characterized by real time RT-PCR, immunofluorescence staining, cell contractile functions, and migration capacity. Our results showed both ECM and fibroblasts induced MSCs differentiation toward VSMC-like cells with increased transcription of marker genes, upregulated expression of contractile apparatus proteins, and enhanced functional activity of VSMC phenotype. Interestingly, our findings revealed that native ECM and fibroblasts-coculture had a higher potential to promote MSCs differentiation into VSMCs than growth factors cocktail (GFC) supplemented culture, thereby providing a potential source of VSMCs for blood vessel constitution.
Collapse
Affiliation(s)
- Na Li
- Department of Biomedical Engineering, University of South Dakota, SD, United States of America; BioSNTR, Sioux Falls, SD, United States of America
| | - Hanna Sanyour
- Department of Biomedical Engineering, University of South Dakota, SD, United States of America; BioSNTR, Sioux Falls, SD, United States of America
| | - Tyler Remund
- Sanford Health, Sioux Falls, SD, United States of America
| | - Patrick Kelly
- Sanford Health, Sioux Falls, SD, United States of America; School of Medicine, University of South Dakota, SD, United States of America
| | - Zhongkui Hong
- Department of Biomedical Engineering, University of South Dakota, SD, United States of America; BioSNTR, Sioux Falls, SD, United States of America.
| |
Collapse
|
5
|
Haldis T, Manchak M, Kouznetsov E, Remund T, Drofa A. Our experience training a neurocardiologist: a case for an emerging specialty. EUROINTERVENTION 2018; 13:1975-1976. [DOI: 10.4244/eij-d-17-00684] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
6
|
Anderson JA, Lamichhane S, Vierhout T, Sherman A, Engebretson D, Pohlson K, Remund T, Kelly P. In vitro particulate and in vivo drug retention study of a novel polyethylene oxide formulation for drug-coated balloons. J Vasc Surg 2017; 67:1537-1545.e7. [PMID: 28843789 DOI: 10.1016/j.jvs.2017.03.442] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Accepted: 03/15/2017] [Indexed: 11/18/2022]
Abstract
OBJECTIVE The purpose of this study was to investigate the newly developed drug-coated balloon (DCB) using polyethylene oxide (PEO) as a platform and to compare it directly with a commercially available DCB in a preclinical experimental setting. METHODS The PEO balloon was characterized for coating morphology and degree of paclitaxel (PAT) crystallinity. PAT tissue levels were then measured up to 30 days in a healthy porcine model (10 swine, 20 vessels) after treatment with either a PEO balloon or a commercially available DCB. An in vitro bench-top model was used to compare the particulates released from the PEO balloon and commercially available DCB. RESULTS The coating on the PEO balloon was smooth and homogeneous with PAT in its amorphous state. From the porcine survival study, the PAT tissue levels were comparable between PEO balloon and commercially available DCB after 7 days of treatment. Both the PEO balloon and the commercially available DCB retained therapeutic drug up to 30 days. During the simulated in vitro model, the PEO balloon shed significantly fewer particulates that were smaller than those of the commercially available DCB. Most important, the PEO balloon shed 25 times fewer large particulates than the commercially available DCB. CONCLUSIONS The amorphous PAT in the PEO balloon provided comparable drug tissue retention levels to those of the commercially available DCB and fewer particulates. Thus prepared PEO balloon proved to be safe and effective in the preclinical experimental setting. The clinical outcomes of these findings need further investigation.
Collapse
Affiliation(s)
- Jordan A Anderson
- Biomedical Engineering Program, University of South Dakota, Sioux Falls, SDak
| | - Sujan Lamichhane
- Biomedical Engineering Program, University of South Dakota, Sioux Falls, SDak
| | - Thomas Vierhout
- Biomedical Engineering Program, University of South Dakota, Sioux Falls, SDak
| | - Andrea Sherman
- Sanford School of Medicine, University of South Dakota, Sioux Falls, SDak
| | - Daniel Engebretson
- Biomedical Engineering Program, University of South Dakota, Sioux Falls, SDak
| | | | | | - Patrick Kelly
- Division of Vascular Surgery, Sanford Health, Sioux Falls, SDak.
| |
Collapse
|
7
|
Lamichhane S, Anderson JA, Vierhout T, Remund T, Sun H, Kelly P. Polytetrafluoroethylene topographies determine the adhesion, activation, and foreign body giant cell formation of macrophages. J Biomed Mater Res A 2017; 105:2441-2450. [DOI: 10.1002/jbm.a.36099] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Revised: 03/06/2017] [Accepted: 04/26/2017] [Indexed: 12/31/2022]
Affiliation(s)
- Sujan Lamichhane
- Biomedical Engineering; The University of South Dakota; 4800 N. Career Avenue Sioux Falls South Dakota 57107
| | - Jordan A. Anderson
- Biomedical Engineering; The University of South Dakota; 4800 N. Career Avenue Sioux Falls South Dakota 57107
| | - Thomas Vierhout
- Biomedical Engineering; The University of South Dakota; 4800 N. Career Avenue Sioux Falls South Dakota 57107
| | - Tyler Remund
- Sanford Research; 2301 East 60 Street North Sioux Falls South Dakota 57104
| | - Hongli Sun
- Biomedical Engineering; The University of South Dakota; 4800 N. Career Avenue Sioux Falls South Dakota 57107
| | - Patrick Kelly
- Sanford Health; 1305 West 18 Street Sioux Falls South Dakota 57105
| |
Collapse
|
8
|
Anderson J, Danielson L, Anderson J, Pohlson K, Remund T, Laurich C, Schultz G, Santos A, Mani G, Kelly P, Shermann A. Pilot Study to Determine Safety and Efficacy of Paclitaxel Infusion in De Novo Peripheral Lesions Using the Atrium ClearWay Balloon. S D Med 2017; 70:109-117. [PMID: 28813772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To evaluate the safety and efficacy of a one-time infusion of paclitaxel through an Atrium ClearWay balloon in infra inguinal de novo peripheral lesions. METHODS This is a single-center prospective study looking at treatment of 50 limbs. Treatment includes standard infra inguinal endovascular revascularization followed by a pre-prescribed infusion of paclitaxel. Control is standard reintervention without subsequent paclitaxel infusion. Patients were followed at one, four, and 10 months with ankle-brachial index (ABI)s, arterial duplex of the treated limb, and Rutherford classification stage measured before and after procedures and at each follow-up. Freedom from binary restenosis was tracked with duplex ultrasound, and freedom from target lesion revascularization (TLR) was also tracked in the treatment group. Binary restenosis and TLR data was harvested from the patient record for the control group. RESULTS Average ABI and Rutherford classification stage improved as expected. The treatment group had a freedom from TLR rate of 86 percent and a freedom from binary restenosis rate of 80 percent at 10 months. Average ABI improved from 0.65 at baseline to 0.94 at 10 months in the treatment group. The control group had a 72 percent freedom from TLR and a 58 percent freedom from binary restenosis at 10 months. Average ABI of the control group improved from 0.67 at baseline to 0.85 at 10 months in the control group. There were no amputations, open bypass revascularizations, or hypersensitivity reactions observed in the treatment group. CONCLUSIONS Infusion of paclitaxel in de novo lesions appears to be a safe and efficacious treatment in the peripheral vasculature when compared to a historical control group. While it is early, it appears that the patients do receive some benefit from this one time infusion, and this approach should be studied further.
Collapse
Affiliation(s)
| | | | - Jodan Anderson
- Biomedical Engineering Department, University of South Dakota
| | | | | | - Chad Laurich
- Sanford Health Vascular Surgery, Sioux Falls, South Dakota
| | - Greg Schultz
- Sanford Health Vascular Surgery, Sioux Falls, South Dakota
| | - Angelo Santos
- Sanford Health Vascular Surgery, Sioux Falls, South Dakota
| | - Gopinath Mani
- Biomedical Engineering Department, University of South Dakota
| | - Patrick Kelly
- Sanford Health Vascular Surgery, Sioux Falls, South Dakota
| | | |
Collapse
|
9
|
Lamichhane S, Anderson JA, Remund T, Sun H, Larson MK, Kelly P, Mani G. Responses of endothelial cells, smooth muscle cells, and platelets dependent on the surface topography of polytetrafluoroethylene. J Biomed Mater Res A 2016; 104:2291-304. [PMID: 27119260 DOI: 10.1002/jbm.a.35763] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Revised: 04/19/2016] [Accepted: 04/25/2016] [Indexed: 11/09/2022]
Abstract
In this study, the effect of different structures (flat, expanded, and electrospun) of polytetrafluoroethylene (PTFE) on the interactions of endothelial cells (ECs), smooth muscle cells (SMCs), and platelets was investigated. In addition, the mechanisms that govern the interactions between ECs, SMCs, and platelets with different structures of PTFE were discussed. The surface characterizations showed that the different structures of PTFE have the same surface chemistry, similar surface wettability and zeta potential, but uniquely different surface topography. The viability, proliferation, morphology, and phenotype of ECs and SMCs interacted with different structures of PTFE were investigated. Expanded PTFE (ePTFE) provided a relatively better surface for the growth of ECs. In case of SMC interactions, although all the different structures of PTFE inhibited SMC growth, a maximum inhibitory effect was observed for ePTFE. In case of platelet interactions, the electrospun PTFE provided a better surface for preventing the adhesion and activation of platelets. Thus, this study demonstrated that the responses of ECs, SMCs, and platelets strongly dependent on the surface topography of the PTFE. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 2291-2304, 2016.
Collapse
Affiliation(s)
- Sujan Lamichhane
- Biomedical Engineering Program, The University of South Dakota, 4800 N. Career Avenue, Sioux Falls, South Dakota, 57107
| | - Jordan A Anderson
- Biomedical Engineering Program, The University of South Dakota, 4800 N. Career Avenue, Sioux Falls, South Dakota, 57107
| | - Tyler Remund
- Sanford Research, 2301 East 60th Street North, Sioux Falls, South Dakota, 57104
| | - Hongli Sun
- Biomedical Engineering Program, The University of South Dakota, 4800 N. Career Avenue, Sioux Falls, South Dakota, 57107
| | - Mark K Larson
- Department of Biology, Augustana University, 2001 S. Summit Avenue, Sioux Falls, South Dakota, 57197
| | - Patrick Kelly
- Sanford Health, 1305 West 18th Street, Sioux Falls, South Dakota, 57105
| | - Gopinath Mani
- Biomedical Engineering Program, The University of South Dakota, 4800 N. Career Avenue, Sioux Falls, South Dakota, 57107
| |
Collapse
|
10
|
Anderson JA, Lamichhane S, Remund T, Kelly P, Mani G. Preparation, characterization, in vitro drug release, and cellular interactions of tailored paclitaxel releasing polyethylene oxide films for drug-coated balloons. Acta Biomater 2016; 29:333-351. [PMID: 26432441 DOI: 10.1016/j.actbio.2015.09.036] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 09/03/2015] [Accepted: 09/28/2015] [Indexed: 10/23/2022]
Abstract
Drug-coated balloons (DCBs) are used to treat various cardiovascular diseases. Currently available DCBs carry drug on the balloon surface either solely or using different carriers. Several studies have shown that a significant amount of drug is lost in the blood stream during balloon tracking to deliver only a sub-therapeutic level of drug at the treatment site. This research is focused on developing paclitaxel (PAT) loaded polyethylene oxide (PEO) films (PAT-PEO) as a controlled drug delivery carrier for DCBs. An array of PAT-PEO films were developed in this study to provide tailored release of >90% of drug only at specific time intervals, which is the time frame required for carrying out balloon-based therapy. The characterizations of PAT-PEO films using SEM, FTIR, and DSC showed that the films developed were homogenous and the PAT was molecularly dispersed in the PEO matrix. Mechanical tests showed that most PAT-PEO films developed were flexible and ductile, with yield and tensile strengths not affected after PAT incorporation. The viability, proliferation, morphology, and phenotype of smooth muscle cells (SMCs) interacted with control-PEO and PAT-PEO films were investigated. All control-PEO and PAT-PEO films showed a significant inhibitory effect on the growth of SMCs, with the degree of inhibition strongly dependent on the w/v% of the polymer used. The PAT-PEO coating was produced on the balloons. The integrity of PAT-PEO coating was well maintained without any mechanical defects occurring during balloon inflation or deflation. The drug release studies showed that only 15% of the total PAT loaded was released from the balloons within the initial 1min (typical balloon tracking time), whereas 80% of the PAT was released between 1min and 4min (typical balloon treatment time). Thus, this study demonstrated the use of PEO as an alternate drug delivery system for the balloons. STATEMENT OF SIGNIFICANCE Atherosclerosis is primarily responsible for cardiovascular diseases (CVDs) in millions of patients every year. Drug-coated balloons (DCBs) are commonly used to treat various CVDs. However, in several currently used DCBs, a significant amount of drug is lost in the blood stream during balloon tracking to deliver only a sub-therapeutic level of drug at the treatment site. In this study, paclitaxel containing polyethylene oxide (PEO) films were developed to provide unique advantages including drug release profiles specifically tailored for balloon-based therapy, homogeneous films with molecularly dispersed drug, flexible and ductile films, and exhibits significant inhibitory effect on smooth muscle cell growth. Thus, this study demonstrated the use of PEO as an alternate drug delivery platform for DCBs to improve its efficacy.
Collapse
|
11
|
Anderson JA, Remund T, Pohlson K, Lamichhane S, Evans C, Evans R, Clark M, Egland K, Kelly P, Mani G. In vitroandin vivoevaluation of effect of excipients in local delivery of paclitaxel using microporous infusion balloon catheters. J Biomed Mater Res B Appl Biomater 2015; 105:376-390. [DOI: 10.1002/jbm.b.33564] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 09/29/2015] [Accepted: 10/14/2015] [Indexed: 11/10/2022]
Affiliation(s)
- Jordan A. Anderson
- Biomedical Engineering; The University of South Dakota; Sioux Falls, South Dakota 57107
| | - Tyler Remund
- Sanford Research; Sioux Falls South Dakota 57104
| | | | - Sujan Lamichhane
- Biomedical Engineering; The University of South Dakota; Sioux Falls, South Dakota 57107
| | - Claire Evans
- Sanford Research; Sioux Falls South Dakota 57104
| | - Rick Evans
- Sanford Research; Sioux Falls South Dakota 57104
| | | | | | | | - Gopinath Mani
- Biomedical Engineering; The University of South Dakota; Sioux Falls, South Dakota 57107
| |
Collapse
|
12
|
Nykamp M, Anderson J, Remund T, Santos A, Laurich C, Schultz G, Kelly P. Use of Physician-Modified Endografts to Repair Unilateral or Bilateral Aortoiliac Aneurysms. Ann Vasc Surg 2015; 29:1468-74. [DOI: 10.1016/j.avsg.2015.04.074] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2014] [Revised: 12/17/2014] [Accepted: 04/12/2015] [Indexed: 02/04/2023]
|
13
|
Suess TN, Gent SP, Remund T, Kelly P. Analysis of Stent-Graft Design for Aortic Aneurysm Repair Using Computational Fluid Dynamics1. J Med Device 2015. [DOI: 10.1115/1.4030574] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Affiliation(s)
- Taylor N. Suess
- Department of Mechanical Engineering, South Dakota State University, Brookings, SD 57006
| | - Stephen P. Gent
- Department of Mechanical Engineering, South Dakota State University, Brookings, SD 57006
| | - Tyler Remund
- Vascular Surgery, Sanford Health, Sioux Falls, SD 57117
| | - Patrick Kelly
- Vascular Surgery, Sanford Health, Sioux Falls, SD 57117
| |
Collapse
|
14
|
Lamichhane S, Anderson J, Remund T, Kelly P, Mani G. Dextran sulfate as a drug delivery platform for drug-coated balloons: Preparation, characterization, in vitro drug elution, and smooth muscle cell response. J Biomed Mater Res B Appl Biomater 2015; 104:1416-30. [PMID: 26227252 PMCID: PMC5054853 DOI: 10.1002/jbm.b.33494] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Revised: 06/12/2015] [Accepted: 07/02/2015] [Indexed: 11/09/2022]
Abstract
Drug‐coated balloons (DCBs) have now emerged as a promising approach to treat peripheral artery disease. However, a significant amount of drug from the balloon surface is lost during balloon tracking and results in delivering only a subtherapeutic dose of drug at the diseased site. Hence, in this study, the use of dextran sulfate (DS) polymer was investigated as a platform to control the drug release from balloons. An antiproliferative drug, paclitaxel (PAT), was incorporated into DS films (PAT‐DS). The characterizations using SEM, FT‐IR, and DSC showed that the films prepared were smooth and homogenous with PAT molecularly dispersed in the bulk of DS matrix in amorphous form. An investigation on the interaction of smooth muscle cells (SMCs) with control‐DS and PAT‐DS films showed that both films inhibited SMC growth, with a superior inhibitory effect observed for PAT‐DS films. PAT‐DS coatings were then produced on balloon catheters. The integrity of coatings was well‐maintained when the balloons were either deflated or inflated. In this study, up to 2.2 µg/mm2 of PAT was loaded on the balloons using the DS platform. Drug elution studies showed that only 10 to 20% of the total PAT loaded was released from the PAT‐DS coated balloons during the typical time period of balloon tracking (1 min) and then ∼80% of the total PAT loaded was released during the typical time period of balloon inflation and treatment (from 1 min to 4 min). Thus, this study demonstrated the use of DS as a platform to control drug delivery from balloons. © 2015 The Authors Journal of Biomedical Materials Research Part B: Applied Biomaterials Published by Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 1416–1430, 2016.
Collapse
Affiliation(s)
- Sujan Lamichhane
- Biomedical Engineering Program, The University of South Dakota, Sioux Falls, South Dakota, 57107
| | - Jordan Anderson
- Biomedical Engineering Program, The University of South Dakota, Sioux Falls, South Dakota, 57107
| | - Tyler Remund
- Sanford Research, Sioux Falls, South Dakota, 57104
| | | | - Gopinath Mani
- Biomedical Engineering Program, The University of South Dakota, Sioux Falls, South Dakota, 57107.
| |
Collapse
|
15
|
Suess T, Anderson J, Danielson L, Pohlson K, Remund T, Blears E, Gent S, Kelly P. Examination of near-wall hemodynamic parameters in the renal bridging stent of various stent graft configurations for repairing visceral branched aortic aneurysms. J Vasc Surg 2015. [PMID: 26209577 DOI: 10.1016/j.jvs.2015.04.421] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVE This study examined the flow behavior of four stent graft configurations for endovascular repair of complex aneurysms of the descending aorta. METHODS Computational fluid dynamics models with transient boundary conditions and rigid wall simplifying assumptions were developed and used with four distinct geometries to compare various near-wall hemodynamic parameters. RESULTS Graphic plots for time-averaged wall shear stress, oscillating shear index, and relative residence time were presented and compared among the four stent graft configurations of interest. CONCLUSIONS Abrupt 90° and 180° changes in stent geometry (particularly in the side branches) cause a high momentum change and thus increased flow separation and mixing, which has significant implications in blood flow characteristics near the wall. By comparison, longer bridging stents provide more gradual changes in momentum, thus allowing blood flow to develop before reaching the target vessel.
Collapse
Affiliation(s)
- Taylor Suess
- Department of Mechanical Engineering, South Dakota State University, Brookings, SDak
| | | | | | | | | | | | - Stephen Gent
- Department of Mechanical Engineering, South Dakota State University, Brookings, SDak
| | | |
Collapse
|
16
|
Anderson J, Remund T, Pohlson K, Kelly P. Description of a new technique for repairing chronic type B dissections that involve visceral branches being fed by both true and false lumen by using both lumens as conduits. Vascular 2015; 24:103-5. [PMID: 25972031 PMCID: PMC4731755 DOI: 10.1177/1708538115586913] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Here we present three cases performed using a novel technique where aortic flow is compartmentalized proximal to the target vessels through a physician-modified endograft. The visceral segment is then further compartmentalized by the use of another physician modified endograft. By compartmentalizing the flow proximal to the visceral segment, both the true lumen and false lumen can be used as conduits for coextensive bridging stent grafts. Overall, patients have tolerated this procedure extremely well, and while further study and follow-up must be conducted, this procedure could offer a reasonable long-term solution to thoracoabdominal aortic aneurysms complicated by dissection.
Collapse
|
17
|
Abstract
Patients suffering from aortic arch aneurysms continue to encounter few treatment options. Because of co-morbidities, most are deemed to not be open surgical candidates. The two cases presented here demonstrate a novel endovascular approach in the care of an arch aneurysm complicated by dissection. Even though final graft configurations differed slightly between the two cases, all three great vessels were successfully de-branched through the combination of standard endovascular aneurysm repair techniques and modifications to off-the-shelf devices. Aortic flow was compartmentalized in the ascending aorta at or near the level of the sinotubular junction. This was done with a physician-assembled endografts. One of these lumens was dedicated to the descending aorta, while the other was further divided into three channels used to stent the great vessels. Completion angiography demonstrated patency in the arch, great vessels, and descending aorta. No endoleaks have been reported. Although data is limited, this approach appears promising.
Collapse
Affiliation(s)
- Joseph Anderson
- Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA
| | - Madeline Nykamp
- Sanford Health, Sanford Vascular Associates, Sioux Falls, SD, USA
| | - Tyler Remund
- Sanford Health, Sanford Vascular Associates, Sioux Falls, SD, USA
| | - Patrick Kelly
- Sanford Health, Sanford Vascular Associates, Sioux Falls, SD, USA
| |
Collapse
|
18
|
Anderson J, Nykamp M, Danielson L, Remund T, Kelly PW. A novel endovascular debranching technique using physician-assembled endografts for repair of thoracoabdominal aneurysms. J Vasc Surg 2014; 60:1177-1184. [PMID: 24997805 DOI: 10.1016/j.jvs.2014.05.090] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2014] [Accepted: 05/14/2014] [Indexed: 11/25/2022]
Abstract
OBJECTIVE The objective of this study was to demonstrate a technique that uses physician-assembled endografts to make use of the benefits of parallel grafts while also providing for circumferential seal and fixation in repair of thoracoabdominal aneurysms in inoperable patients. METHODS A single-center all-comers retrospective analysis of 14 patients was performed that looked at the early outcomes of patients treated for thoracoabdominal aneurysms. Three Crawford type II, four type III, four type IV, and three type V thoracoabdominal aneurysms were treated. Contrast material, fluoroscopy time, length of stay, clinical success, and technical success were measured. RESULTS There was no in-hospital, 30-day, or 6-month mortality. We found two type III endoleaks in the early design. One required coil embolization. Average volume of contrast material and average fluoroscopy time were 76.9 mL and 119.1 minutes, respectively. Average length of stay was 10.5 days, and average procedure time was 251.2 minutes. Clinical success was observed in 78.6% of patients to date, and technical success was observed in 85.7% of patients. CONCLUSIONS Short-term results show that this approach is safe. The device can be safely implanted, is off-the-shelf, and can treat each of the Crawford thoracoabdominal aneurysm types. Finally, the assembly of off-the-shelf components may shorten the regulatory path for this physician-assembled endograft.
Collapse
Affiliation(s)
- Joe Anderson
- Sanford School of Medicine, University of South Dakota, Sioux Falls, SDak
| | | | - Laura Danielson
- Sanford School of Medicine, University of South Dakota, Sioux Falls, SDak
| | | | | |
Collapse
|
19
|
Danielson L, Anderson J, Nykamp M, Remund T, Kelly P. Treatment of a massive left femoral arteriovenous malformation using an innovative modular hybrid bifurcated stent graft system. Ann Vasc Surg 2013; 28:1031.e15-20. [PMID: 24184461 DOI: 10.1016/j.avsg.2013.07.023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2013] [Revised: 07/28/2013] [Accepted: 07/31/2013] [Indexed: 11/20/2022]
Abstract
BACKGROUND Arteriovenous malformations (AVMs) are difficult to treat and manage because of their high recurrence and complication rates. In particular, peripheral AVMs pose multiple clinical challenges because of their high flow rates and the frequent presence of multifocal nidi. METHODS A 37-year-old man with a massive AVM involving the left common, deep, and superficial femoral arteries and veins is discussed herein. After initially being treated at another facility with coil embolization in 2005, he went untreated until he presented to us in April 2012 with swelling, tissue breakdown, leg ulcers, pain, and difficulty walking. When our extensive packed coil embolization proved ineffective, we knew that other standard treatments would be impractical, given the size of the AVM. Because the patient was in significant danger of bleeding, we treated him endovascularly with a system of modified stent grafts to exclude the arterial branches feeding multiple nidi. RESULTS Postoperative computed tomography angiography scans revealed exclusion of the AVM and excellent flow to the deep and superficial femoral arteries. At 6 months postoperatively, the patient had no complications, and the leg continued to decompress. At 8 months postoperatively, we started additional treatment using percutaneous sclerotherapy to treat residual areas. CONCLUSION A modular hybrid bifurcated stent graft system is a viable option to treat or manage complex peripheral arteriovenous malformations.
Collapse
|